Molecular Imaging 2017

1066 / 1241

Treatment Response Assessment
Tumour Type Treatment Imaging Findings Author, Year
Symptomatic
Myeloma:
Mixed
population
n=34
13 weeks
Cyclophosphamide
Lenalidomide ,
Bortezomib,
Dexamethasone
DWI50-900
T1, STIR
Increase in ADC
with treatment
SN: 86%, SP:
80%, PPVadj :
94.5%, NPVadj:
59%; prevalence
of response: 80%
Giles et al, 2014
Symptomatic
Myeloma
n=12
3 weeks
Treatment not
stated
DWI50-800
T1, STIR
Increase in ADC
with treatment
Horger et al,
2011
Symptomatic
Myeloma
n=20
4-6 weeks
20 weeks
Cyclophosphamide
Thalidomide
Dexamethasone
DWI
T1, STIR
Increase in ADC
with treatment
Messiou et al
2012